Abstract
Gemcitabine, a novel anticancer agent, was demonstrated to be well tolerated in both elderly and younger patients. Safety data were collected from 18 completed clinical studies (790 patients) in a variety of solid tumor types. All studies used a starting dose of 800–1250 mg/m2 administered once a week for 3 weeks followed by a week of rest. Patients were initially divided using a cut-off age of 65 years, and subsequently using a cut-off age of 70 years. Gemcitabine was well tolerated by patients of all ages, with few clinically meaningful differences between the age groups. Gemcitabine was also found to be as efficacious in older patients as in younger ones. Efficacy data was collected from four studies (329 evaluable patients) in non-small cell lung cancer with consistent response rates of 20%. When patients were divided into two groups, those aged below 70 years and those 70 years and above, the response rates were 19.0% (95% C.I., 14.6–23.4) and 25.0% (95% C.I., 10.0–40.0) respectively. In conclusion, elderly patients should benefit from gemcitabine treatment.
Similar content being viewed by others
References
Phister J.E., Jue S.E., Cusack B.J.: Problems in the use of anticancer drugs in the elderly. Drugs 37: 551–565, 1989.
Walsh S.J., Begg C.B., Carbone P.P.: Cancer chemotherapy in the elderly. Semin. Oncol. 16: 66–75, 1989.
Grindey G.G., Boder G.B., Hertel L.H., Kroin J.S., Poore G.A., Rinzel S.M., Todd G.C.: Antitumor activity of 2′,2′-difluorodeoxycitidine (LY188011). Proc. Am. Assoc. Cancer Res. 27, 1986, p. 296 (A 1775).
Chubb S., Heinemann V., Novotny L., Hertel L., Nowak B., Mineishi S., Grindey G.B., Plunkett W.: Metabolism and action of 2′,2′-difluorodeoxycytidine (dFdC) in human leukemia cell. Proc. Am. Assoc. Cancer Res. 28, 1987, p. 324 (A 1282).
Bhalla K., MacLaughlin W., Cole J., Arlin Z., Birkhofer M., Graham G.: Continuously administered 2′,2′-difluorodeoxycytidine (dFdC) and deoxycytidine (dCyd): A potentially selective cytotoxic regimen toward human leukemic myeloid progenitors in culture. Proc. Am. Assoc. Cancer Res. 28, 1988, p. 348 (A 1385).
Fujita F., Fijita M., Inaba H., Taguchi T.: Antitumor activity of LY188011, a new deoxycytidine analog, against human cancers xenografted into nude mice. Jpn. J. Cancer Chemother. 21: 517–523, 1994.
Tanayanagi C., Takauji R., Ueda T.: Action mechanism of difluorodeoxycitidine (dFdC), a new ara-C derivative. Acta Hematol. Jpn. 53: 76, 1990 (A 132).
Bouffard D.Y., Momparler L.F., Momparler R.L.: Comparison of antineoplastic activity of cytosine arabinoside and 2′,2′-difluorodeoxycytidine on human myelod, T-cell and B-cell leukemic cells. Eur. J. Pharmacol. 183, 161, 1990 (A 32).
Plunkett W., Chubb S., Nowak B., Hertel L., Grindey G.B.: Increased cytotoxicity and therapeutic activity of 2′,2′-difluorodeoxycytidine over cytosine arabinoside (ara-C) in L1210 leukemia. Proc. Am. Assoc. Cancer Res. 29, 1988, p. 352
Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H.H.: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J. Clin. Oncol. 12: 1821–1826, 1994.
Gatzemeier U., Shepherd F.A., Le Chevalier T., Weynants P., Cottier B., Groen H.J., Rosso R., Mattson K., Cortes-Funes H., Tonato M., Burkes R.L., Gottfried M., Voi M.: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study. Eur. J. Cancer 32: 243–248, 1996.
Kaye S.B.: Gemcitabine current status of phase I and II trials. J. Clin. Oncol. 12: 1527–1531, 1994.
Abratt R.P., Werner R.B., Falkson G., Goedhals L., Hacking D., Rugg T.: Efficacy and safety of gemcitabine in non-small cell lung cancer: A phase II Study. J. Clin. Oncol. 12: 1535–1540, 1994.
Walling J.: Chemotherapy of advanced non-small cell lung cancer. Respir. Med. 88: 649–657, 1994.
Carmichael J., Fink U., Russell R.C.G., Spittle M.F., Harris A.L., Spiessi G., Blatter J.: Phase II Study of gemcitabine in patients with advanced pancreas cancer. Br. J. Cancer 73: 101–105, 1996.
Casper E.S., Green M.R., Kelsen D.P., Heelan R.T., Brown T.D., Flombaum C.D., Trochanowski B., Tarassoff P.G.: Phase II trial of gemcitabine (2′,2′difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 12: 29–34, 1994.
Lund B., Hansen O.P., Theilade K., Hansen M., Neijt J.P.: Phase II study of gemcitabine (2′,2′-difluorodeoxycitidine) in previously treated ovarian cancer. J. Natl. Cancer Inst. 86: 1530–1533, 1994.
Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., Harris A.L.: Advanced breast cancer: A Phase II trial with gemcitabine. J. Clin. Oncol. 13: 2731–2736, 1995.
Cormier Y., Eisenhauer E., Muldal A., Gregg R., Ayoub J., Gross G., Stewart D., Tarasoff P., Wong D.: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann. Oncol. 5: 283–285, 1994.
De Mulder P.H.M., Weissbach L., Jakse G., Osieka R., Blatter J.: Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother. Pharmacol. 37: 491–495, 1996.
Merterns W.C., Eisenhauer E.A., Moore M., et al.: Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials group. Ann. Oncol. 4: 331–332, 1994.
Abbruzzese J.L., Pazdur R., Ajani J., Daugherty K., Tarassoff P., Levin B.: A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 10: 456, 1991.
Christman K., Kelsen D., Saltz L., Tarassoff P.G.: Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 73: 5–7, 1994.
Poplin P., Thompson B., Whitacre M.: Small cell carcinoma of the lung: influence of age on treatment outcome. Cancer Treat. Rep. 71: 290–296, 1987.
Rinaldi M., De Marinis F., Ardizzoni A.: Correlation between age and prognosis in patients with advanced non small cell cancer (NSCLC) treated with cisplatin (CDDP) containing chemotherapy: a retrospective multicenter study. Ann. Oncol. 5 (Suppl. 8): 58, 1994.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martin, C., Ardizzoni, A. & Rosso, R. Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging Clin Exp Res 9, 297–303 (1997). https://doi.org/10.1007/BF03341832
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03341832